

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia

Information for the public
Published: 12 August 2020

www.nice.org.uk

Gilteritinib (Xospata) is available on the NHS as a possible treatment for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia (AML) in adults. But it should not be offered to you after you have had a haematopoietic stem cell transplant.

If you are not eligible for gilteritinib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Care](#), 08088 010 444
- [Blood Cancer UK](#), 0808 2080 888
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3845-2